<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT932-13898</title>
	</head>
	<body>
		<main>
			<p>930421 FT  21 APR 93 / International Company News: Pfizer posts 25% rise in first period PFIZER, one of the fastest-growing US drugs companies, yesterday posted a 25 per cent rise in first-quarter underlying earnings from continuing operations, writes Karen Zagor. Net income for the 1993 first quarter was Dollars 329m, or Dollars 1.01 a share, on sales of Dollars 1.87bn, compared with earnings of Dollars 14.8m, or 4 cents, on sales of Dollars 1.76bn a year earlier. Accounting changes reduced 1992 earnings by Dollars 312.6m. Pfizer has divested and closed businesses and took restructuring charges in both years. Excluding unusual items, Pfizer said net income from ongoing operations was Dollars 350.3m, or Dollars 1.07, on sales of Dollars 1.86bn in the latest quarter against earnings of Dollars 279.8m, or 83 cents, on sales of Dollars 1.63bn a year earlier. Mr William Steere, chairman and chief executive, said: 'Virtually all our sales growth was from increased volume. Of our 15 per cent sales growth from ongoing operations, 16 per cent was from volume, 2 per cent from price increases, and the strengthening of the dollar reduced sales growth by 3 per cent.'</p>
		</main>
</body></html>
            